Navigation Links
Partnership to Prevent HIV Among Vulnerable Russian Youth
Date:3/18/2009

USAID, HealthRight International and Johnson & Johnson formalize a partnership to prevent the spread of HIV among street children and at-risk youth in St. Petersburg, Russia.

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- A public-private partnership to prevent the spread of HIV and increase access to HIV treatment and care among street children and other vulnerable youth in St. Petersburg, Russia was announced by the United States Agency for International Development (USAID), HealthRight International and Johnson & Johnson at the signing of a Memorandum of Cooperation today.

Estimates indicate that there are up to 10,000 street children and youth in St. Petersburg, many of whom struggle with substance abuse and other risky behaviors. Studies demonstrate extremely high rates of HIV transmission (37.4%) among this group, who have limited access to clinical treatment and care.

With support from USAID's Russia program and Johnson & Johnson, HealthRight International (formerly Doctors of the World-USA) together with its local partner, Doctors to Children, will reach 500 vulnerable youth with effective HIV prevention messages and a broad continuum of services, including mobile voluntary testing for HIV and referrals to treatment and care. The project will also develop a cadre of social workers trained in HIV prevention among street youth and disseminate a package of HIV prevention best practices to government institutions and non-governmental organizations (NGOs) across St. Petersburg.

"We are very pleased to join Johnson & Johnson and HealthRight International in a partnership to reach the most vulnerable youth with critically needed HIV prevention messages and services," said Leon Waskin, USAID's Director in Russia. "This initiative builds on a previous collaboration that has demonstrated the impact we can achieve when we combine our resources a
'/>"/>

SOURCE U.S. Agency for International Development
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Siemens to Donate Hearing Instruments Through Second Annual Partnership With Quota International
2. MAGNET Cooperative and Procurex, Inc. Announce Integration Partnership Streamlining the Healthcare Industry's Purchasing Process
3. Irish-Owned Heritage Casket Company Strikes Multi-Million-Dollar Partnership Deal With Pennsylvanias Matthews International
4. Practice Greenhealth Enters Partnership with Johnson & Johnson for Health Care Sustainability Research and Training
5. Pasadena Marathon Presented By Kaiser Permanente Hails Partnership With Tiffany & Co.
6. The Partnership for a Drug-Free America Lauds Kerlikowske as New Director of Office of National Drug Control Policy
7. CBCA Administrators, Inc. Announces Strategic Partnership with KePRO
8. Nortech Labs, Inc. and MEDNET(TM) Make for a Notable, Natural Partnership
9. ACSM Partnership Will Combat Childhood Obesity, Get Kids Active
10. University of Maryland Business School Continues Executive Education Leadership With Maryland State Medical Society Partnership
11. Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , , PEMBROKE, Bermuda, Dec. 4 /PRN...ny Holdings, Ltd (NYSE: AWH ) today announced th...Officer, and Jack Sennott, Executive Vice,Presiden...esenting at the 2009,Goldman Sachs U.S. Financial ...s Conference Center in New York City on Tuesday, D...
(Date:12/4/2009)... , , MADISON HEIGHTS, Mich., Dec...urities Review Committee of BetterInvesting Magaz... ) as its February 2010 "Stock to Study" and C.R....Undervalued Stock" for investors, informational an...rgan because of growth opportunities involving its...
(Date:12/4/2009)... , Late recurrence is a risk for some pediatric c...the central nervous system, according to a new stu...the National Cancer Institute . , This study was...ate recurrence (after 5 years and up to 20 years) ...i-Masker, M.D., of the Aflac Cancer Center and Blo...
(Date:12/4/2009)... , More than 15 million Americans are recruited...ing to the Alliance for Human Research Protection ...ticipation. , Research institutions view pay...xpenses; not as compensation for potential risks r... new study finds that volunteers have a very diffe...
(Date:12/4/2009)... Increasing exercise, water and fruit consumptio...IDAY, Dec. 4 (HealthDay News) -- Increased exercis...among the most effective weight control strategies...ers surveyed 130 adolescents about their weight-co...ad succeeded in losing weight and 68 had not. The ...
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2
...genital Heart Disease published recently in the Eu...ty of adult heart care and the extent of its defic...improvement in the treatment of pediatric heart di...of the patients and list the deficient areas. 71 c...
... by researchers at Columbia University Medical Cen... rates and adherence to cancer treatment, //it has...had stopped their chemotherapy. More specifically,...efore completion. Non-compliance rates in th...
...rs at University of Manchester now reveals that sp...iseases, Vascular Dementia and Alzheimer's disease...sh Medical Journal (BMJ). This finding could e...d vascular dementia can account for a major propor...
...n 2004 the sales of Celebrex was $3.3 billion worl...g causing heart attacks the company stopped advert...he consumer ad market in hopes of reviving sales o...oost it sales. Each ad includes a boldface warnin...
...quently among children. It is one of the diseases ...ow 3 months of age//. Hence Dr. Lawrence S. Eichen...an Diego and colleagues came up with the fluticaso...en compared to ointments and creams. It is very he...
...ssion of senile amyloidosis to offspring from affe...om mother to child// have been raised. Details abo...is in offspring of mice with AApoAII amyloidosis,'...including amyloidosis. Amyloidosis occurs when cel...
Other Medicine News:Health News:Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy 2Health News:Doubts About In UteroTransmission Of Senile Amyloidosis 2
(Date:12/3/2009)...DOYLESTOWN, Pa., Dec. 3 ...ation, (Nasdaq: QGLY ) www.quigleyco.com announ...ation of its opportunities to develop prescription... that it is in its best interests to focus primari... include but are not limited to its Cold-EEZE®...
(Date:12/3/2009)..., WARRENDALE, Pa., Dec. 3 Radiol... injection-record integration capabilities at the ...n Chicago. The Connect.PACS(TM) product, enabli... its kind, is the latest release in the company,s ... ,, (Photo: http://www.newscom.com/cgi-bin/...
(Date:12/3/2009)..., HOERSHOLM, Denmark and SAN DIEGO, Californi... Successfully Inhibits miR-122, a microRNA Importa...ificantly Reducing Hepatitis C,Virus in the Bloods...,Hepatitis C Virus , - SPC3649 Demonstrat...nd,No Serious Adverse Events in the Treated Animal...
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 1Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 2Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 3Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 4Genes May Raise Risk of Neuroblastoma in Kids 49265 1Genes May Raise Risk of Neuroblastoma in Kids 49265 2Genes May Raise Risk of Neuroblastoma in Kids 49265 3Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 1Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 2
...AL GABLES, Fla., Jan. 9 Catalyst,Pharmaceutical P...al company that,acquires, in-licenses, develops an...ent of drug addiction, announced today that it has...e II trial evaluating CPP-109 for the treatment,of...ormulation of vigabatrin,being developed as a trea...
... Switzerland, Jan. 9 ESBATech AG, a leading develo...nced the initiation of the Phase I/IIa clinical de...ESBA105 in osteoarthritis (OA). This double-blind,...al study is designed to investigate the safety, to...ed locally via intra-articular administration to p...
Other Medicine Technology:Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 2Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: